Drug pricing in Japan is no longer a technical exercise. It has become a frontline issue in social security reform and fiscal politics. Examining the FY2026 drug price revision through the interplay of political leadership, public–private dialogue, and Chuikyo’s institutional process, GR Japan provides insight into how pricing outcomes are shaped and what they mean for pharmaceutical strategy and Government Relations in Japan.

For a detailed analysis and full findings, please read the attached PDF report.